ArticleIranian journal of basic medical sciences2025
Cardioprotective effects of lycopene-loaded nanoparticles against isoproterenol-induced myocardial injury.
Article in Iranian journal of basic medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to investigate the cardioprotective effects of lycopene loaded ovalbumin chitosan nanoparticle (L-OCNPs) against isoproterenol (ISO)-induced myocardial injury. Materials and Methods: H9c2 cardiomyoblasts were treated with various concentrations of L-OCNPs (5, 10, 15, 25, and 50 µg/ml) for 24 hr, followed by exposure to ISO (100 µM) for an additional 24 hr. Cell viability, oxidative stress, mitochondrial function, and nuclear damage were assessed using various biochemical and molecular techniques. Molecular docking studies were conducted to explore the binding interactions between L-OCNPs and the Nrf2 protein. Results: L-OCNPs exhibited significant cytoprotective effects against ISO-induced cytotoxicity. They effectively reduced oxidative stress by scavenging reactive oxygen species and up-regulating antioxidant enzymes. L-OCNPs also preserved mitochondrial function by maintaining mitochondrial membrane potential and reducing mitochondrial damage. Furthermore, they protected against nuclear damage by inhibiting DNA fragmentation and apoptosis. Molecular docking studies revealed that L-OCNPs, particularly (all-E)-Lycopene and 5Z-Lycopene, interact with the Nrf2 protein, suggesting a potential mechanism of action. Histopathological analysis of rat hearts confirmed the cardioprotective effects of L-OCNPs against ISO-induced myocardial injury. Conclusion: L-OCNPs demonstrate promising cardioprotective properties by mitigating oxidative stress, preserving mitochondrial function, and preventing nuclear damage. These outcomes propose that L-OCNPs may be a potential therapeutic agent for the prevention and treatment of cardiovascular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.